What we do Hamps Bio Limited markets and distributes pharmaceutical formulations and manufactures freeze-dried and frozen FMCG products under brands 'Hamps' and 'FzyEzy'. |
Founded in 2,007 |
Market share Operates across multiple Indian states in pharma; exports FMCG products to four countries with growing distributor network. |
Problem solved Provides quality pharmaceutical and nutritious freeze-dried products addressing healthcare and consumer food needs. |
Top clients or who we serve Pharmaceutical distributors and retailers primarily in eight Indian states; FMCG products sold domestically and internationally via e-commerce platforms. |
Key management Herrik Mountbaton Shah (Managing Director), Shrenikkumar Mountkumar Shah (Whole-time Director), Mitali Shrenikkumar Shah (CFO) |
Our journey and innovations Started pharma marketing in 2007; expanded into freeze-dried FMCG products in 2017; launched solar power plant and new freeze drying plant in 2025. |
Where we operate India (8 states for pharma, 22 states for FMCG), and FMCG exports to four countries. |
Top products or what we offer Pharmaceutical formulations including tablets, syrups, injectables; freeze-dried fruits, vegetables, herbs under 'FzyEzy'. |
Top brands Hamps (pharma formulations), FzyEzy (freeze-dried and frozen foods) |
Raw materials needed Pharmaceutical ingredients and fresh produce such as fruits, vegetables, herbs, and flowers. |
Raw materials supplier Contract manufacturers with WHO GMP certification supply pharma ingredients; local sourcing for fresh produce. |
Recurring vs cyclical contribution Revenue includes recurring pharma sales and growing FMCG segment driven by expanding exports and e-commerce. |
Our industry position Mid-sized player in pharma marketing and FMCG freeze-dried processing with increasing market presence and export focus. |
Financial highlights FY2025 revenue of ₹6.67 crore with net profit ₹0.30 crore; steady growth driven by new plant operations and IPO funding. |
Geographical revenue split Primarily Indian states for pharma products; FMCG exports contribute to revenue from four countries. |
Order book - |
Whats driving growth New freeze-drying facility, solar power adoption, expanding distributor network and e-commerce channels fueling growth. |
Our future plans Enhance export volumes by 30% and continue investing IPO proceeds in plant expansion and brand awareness. |
Our green promise Commissioned 350 kVA solar plant at Ankleshwar to support sustainable production and reduce carbon footprint. |
Our people and values Focus on ethical marketing, corporate governance, and strong board oversight with experienced leadership team. |
Key challenges ahead Expanding competitive FMCG and pharma markets require continuous innovation and operational efficiency. |
Interesting facts Successful IPO on BSE SME with ₹6.22 crore raised for expansion; dual presence in pharma and FMCG sectors. |
Risks and strategy Managing supply chain quality and regulatory compliance with robust risk management and vigilant board oversight. |
